The content on this site is intended for healthcare professionals only
Dr Brentjens talks to ecancertv at TAT 2015 about chimeric antigen receptor (CAR) T cell therapy, outlining how it has been used with great success to treat patients with B-cell cancers.
He also discusses some of the practicalities and challenges of using this approach in clinical practice.
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Multiple myeloma In Rwanda: The need for further research
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
